Key result
Early initiation of combination therapy with ACE-I/ARB and β-blockers during hospitalization for HFmr/pEF is associated with a lower risk of all-cause death or heart failure readmission.
Why the study?
Does early initiation of combination therapy (ACE-I/ARB and beta-blockers) reduce all-cause death or heart failure readmission in patients hospitalized with HFmr/pEF?
Does early initiation of combination therapy (ACE-I/ARB and beta-blockers) reduce all-cause death or heart failure readmission in patients hospitalized with HFmr/pEF?
Early initiation of multiple antineurohormonal medications during hospitalization for patients with HFmr/pEF who are naïve to these drugs is safe and potentially favorable in terms of outcomes.
treatment guidelines with preserved LVEF.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted an editorial in Heart failure with mid-range or preserved ejection fraction (HFmr/pEF) (n=858). Combination therapy (ACE-I/ARB and β-blockers) vs. No ACE-I/ARB or β-blockers was evaluated on All-cause death or heart failure readmission. Early initiation of combination therapy with ACE-I/ARB and β-blockers during hospitalization for HFmr/pEF is associated with a lower risk of all-cause death or heart failure readmission.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: